IMR.ASX: Imricor U.S. Commercial Momentum Accelerates

Imricor U.S. Commercial Momentum Accelerates

Stock	Imricor Medical Systems Inc (IMR.ASX)
Release Time	10 Aug 2026, 8:50 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Imricor Secures Second U.S. Customer for NorthStar System

Key Points

Children's Medical Center Dallas becomes second U.S. customer
Installation in existing Philips iMR lab with no construction required
NorthStar to enable 100% radiation-free cardiac catheterization procedures

Full Summary

Imricor Medical Systems, Inc. (ASX: IMR) has announced that Children's Medical Center Dallas will adopt its NorthStar interventional magnetic resonance (iMR) mapping and guidance system. This marks the second U.S. hospital to purchase the NorthStar system, following Rady Children's Hospital-San Diego. Children's Medical Center Dallas, a leading pediatric healthcare provider, will utilize the NorthStar system in its existing Philips iMR lab, eliminating the need for lab construction. The hospital plans to launch a NorthStar-guided iMR cardiac catheterization program, offering 100% radiation-free procedures for children with congenital heart disease. This adoption validates the commercial momentum behind Imricor's U.S. launch and the newly established Imricor Cardiovascular vertical.